Platform

InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modeling and simulation in pharmaceutical and medical devices development

How does it work?

The platform offers users two computational options:

  • to select the model of choice from the digital library
  • to develop or to upload their own model

The platform enables users to input parameters of choice into the model. For a model from the digital library, parameters choices are guided by best practice ranges.
Simulations are launched and run on protected and secured Microsoft Azure Cloud computing resources.
Completion of the modeling and simulation is notified to the users via e-mail.
The platform enables users to view and analyze the modeling and simulation results and to optimize modeling and simulation scenario’s depending on objectives.

QT/TdP Risk Screen

A new assessment tool that facilitates the prediction of the proarrhythmic risk of a wide range of drugs without carrying out time-consuming simulations during preclinical screening.

Arrhythmogenic indices like Tx (drug concentration leading to a 10% prolongation of the action potential over the effective free therapeutic plasma concentration), TqNet (net charge carried by ionic currents when exposed to 10 times the effective free therapeutic plasma concentration ) and Ttriang (triangulation for a drug concentration of 10 times the effective free therapeutic plasma concentration over triangulation in control) were precomputed for a large combination of currents block values with respect to the 3-current combinations IKr, ICaL, IKs and IKr, ICaL, INaL .

Power of prediction was enhanced by combining Tx, TqNet and Ttriang for the two combinations in one classifier based on decision trees achieving a classification accuracy of 94.5% for a dataset of 109 drugs of known torsadogenic risk (51 positive). This TdP risk classification can be as accurate as when considering effects on the seven main ion currents proposed by the CiPA initiative.

QT/TdP Risk Screen is a ready-to-use tool based on more than 450 000 simulations, which can be easily employed to quickly assess the proarrhythmic risk of libraries of compounds.

STrhiPS

A new assessment tool that enables the in silico reconstruction of the human ventricular action potential with cellular studies performed on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to predict the proarrhythmic liability of drug candidates.

For each candidate cardiac safety markers are estimated on the number of cells of your choice in presence (dosed) or absence (control) of the drug concentration of interest. Simulation results include cell classifications (with or without abnormalities, quiescence), markers descriptive statistics and distributions. Action potential traces can be visualized for each individual cell before and after dosing.

The assessment of hiPSC-CM electrophysiological variability in cells by means of populations of in silico hiPSC-CMs is rapidly becoming a relevant component of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative.

NuMRis

NuMRis is the tool of the InSilicoMRI library for the investigation of the radiofrequency (RF)-induced heating of passive devices in a MRI scanner.

One of the possible risks posed to a patient with implanted devices during MRI is that conductive structures may pick up RF-energy during the exposure, and locally deposit it as heating in tissue near the implant. To assess the compatibility level, the manufacturer of the medical device has to perform tests to predict the hazard in the worst-case exposure scenario. NuMRis is designed to study the MRI compatibility, for different exposure conditions, of implantable devices (e.g. stents) with different dimensions, configurations or designs. The user can choose to upload his own device or chose a simplified geometry form the tool library.

NuMRis has been implemented in collaboration with the FDA and ANSYS to support the broadening use of computer modeling and simulation for electromagnetic safety analysis prior to a medical device submission. The models of the RF exposure system used in the simulation were provided by the Center for Devices and Radiological Health within the U.S. Food and Drug Administration (FDA-CDRH). The simulation steps are designed following the ASTM F2182-19e2 Standard.

Software

InSilicoTrials enables you to run the model of your choice with widely adopted software in a pre-configured and integrated framework, and you pay what you use. Engineers, designers, researchers, clinicians use our technological solutions for product design, development, testing and decision making.

ANSYS, the global leader in engineering simulation, provides engineering simulation software to help customers solve the most complex design challenges and engineer successful, innovative products faster and at lower cost.

Cloud

InSilicoTrials allows you to run your simulations on scalable and on-demand computing resources, tailored on your modeling needs.
The cloud-based computational hub is conform to global standards and grants data protection and cybersecurity.

Azure offers a platform to develop solutions for in silico medicine and personalized healthcare, providing on-demand compute resources that enable to run large parallel and batch compute jobs in the cloud.